Genentech has secured a second marketed stroke therapy after the US Food and Drug Administration (FDA) approved a label ...

Against all the odds, Roche's Genentech unit has won FDA approval for its clot-busting drug TNKase as a treatment for acute ischaemic stroke, after all but abandoning the project a couple of years ...

Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...

“Today’s approval is a significant step forward and underscores our commitment to advancing stroke treatment options ... of Global Product Development at Genentech. “TNKase provides a ...

Repertoire Immune Medicines has signed a partnership and licensing agreement with Roche’s Genentech, focusing on the discovery and development of T cell-targeted immune medicines for treating an ...

Roche’s Genentech unit and Repertoire Immune Medicines have entered into a partnership worth $765m to discover and develop T cell-targeted immune medicines for an undisclosed autoimmune disease. The ...